Late-breaking data presented from INTEGUMENT-PED phase III trial of roflumilast cream 0.05% in atopic dermatitis in children ages 2 to 5 at the AAD meeting
Arcutis Biotherapeutics, Inc., presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (San Diego, CA, March 8 – 12) new data from its INTEGUMENT-PED pivotal Phase III study of investigational roflumilast cream 0.05% in children 2 to 5 years of age with mild to moderate atopic dermatitis